These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22302226)

  • 1. Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?
    Theriault RL
    Oncologist; 2012; 17(2):157-9. PubMed ID: 22302226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise of antibody-drug conjugates.
    Teicher BA; Doroshow JH
    N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 4. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab: qui bono?
    Krop IE; Burstein HJ
    J Natl Cancer Inst; 2013 Dec; 105(23):1772-5. PubMed ID: 24262439
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to a. Avan et Al.
    Baselga J; Clark E; Kiermaier A; Swain SM
    J Clin Oncol; 2015 May; 33(15):1712. PubMed ID: 25870094
    [No Abstract]   [Full Text] [Related]  

  • 8. How should HER2 status be determined?
    McNeil C
    J Natl Cancer Inst; 1999 Jan; 91(2):111. PubMed ID: 9923849
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Jul; 11(7):379. PubMed ID: 24913372
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
    Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
    J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.
    Rodrigues MJ; Albiges-Sauvin L; Wassermann J; Cottu PH
    Ann Oncol; 2011 Nov; 22(11):2530. PubMed ID: 21700734
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

  • 14. Can HER2 status predict response to cancer therapy?
    Nelson NJ
    J Natl Cancer Inst; 2000 Mar; 92(5):366-7. PubMed ID: 10699062
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 16. Ado-trastuzumab emtansine approved for advanced breast cancer.
    Traynor K
    Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert.
    Torresi U
    Ann Oncol; 2008 Jan; 19(1):191. PubMed ID: 18165702
    [No Abstract]   [Full Text] [Related]  

  • 18. Duration of trastuzumab for HER2-positive breast cancer.
    Montemurro F; Aglietta M
    Lancet Oncol; 2013 Jul; 14(8):678-9. PubMed ID: 23764182
    [No Abstract]   [Full Text] [Related]  

  • 19. [HER2 testing in breast cancer].
    Yoshimura K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
    [No Abstract]   [Full Text] [Related]  

  • 20. PrefHer: finally addressing the preferences of her, too.
    Melichar B
    Lancet Oncol; 2013 Sep; 14(10):914-5. PubMed ID: 23965224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.